Literature DB >> 1982904

Effect of NMDA- and strychnine-insensitive glycine site antagonists on NMDA-mediated convulsions and learning.

C Chiamulera1, S Costa, A Reggiani.   

Abstract

Intracerebroventricular (ICV) injection of N-methyl-D-aspartate (NMDA) was shown to induce generalized seizures in mice. The competitive NMDA antagonists DL-2-amino-5-phosphonovaleroate (DL-AP7) and 3-(2-carboxypiperazin-4-yl)propyl-1-phosphonate (CPP), the NMDA "channel blocker" antagonist (+)-5-methyl-10,11-dihydro 5H-dibenzo-[a,d] cycloheptan-5,10-imine maleate (MK-801) and the strychnine-insensitive glycine antagonists kynurenic acid (KYNA) and 7-chloro-kynurenic acid (7-Cl-KYNA), when co-administered (ICV) with NMDA, antagonized NMDA-induced generalized seizures. Administration (ICV) of DL-AP7, CPP and MK-801 resulted in impared learning performance in a passive avoidance task in mice, with ED50 close to the anticonvulsant dose. The glycine antagonists KYNA and 7-Cl-KYNA at high doses significantly failed to affect performance in the same model of learning. The results indicate that compounds acting at the strychnine-insensitive glycine site may have a larger "therapeutic window" as anticonvulsants than antagonists of the NMDA receptor and channel.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1982904     DOI: 10.1007/bf02247140

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  7 in total

1.  A simplified method of evaluating dose-effect experiments.

Authors:  J T LITCHFIELD; F WILCOXON
Journal:  J Pharmacol Exp Ther       Date:  1949-06       Impact factor: 4.030

Review 2.  Structure-activity relationships in the development of excitatory amino acid receptor agonists and competitive antagonists.

Authors:  J C Watkins; P Krogsgaard-Larsen; T Honoré
Journal:  Trends Pharmacol Sci       Date:  1990-01       Impact factor: 14.819

Review 3.  Noncompetitive excitatory amino acid receptor antagonists.

Authors:  D Lodge; K M Johnson
Journal:  Trends Pharmacol Sci       Date:  1990-02       Impact factor: 14.819

4.  Selective blockade of N-methyl-D-aspartate (NMDA)-induced convulsions by NMDA antagonists and putative glycine antagonists: relationship with phencyclidine-like behavioral effects.

Authors:  W Koek; F C Colpaert
Journal:  J Pharmacol Exp Ther       Date:  1990-01       Impact factor: 4.030

5.  Selective impairment of learning and blockade of long-term potentiation by an N-methyl-D-aspartate receptor antagonist, AP5.

Authors:  R G Morris; E Anderson; G S Lynch; M Baudry
Journal:  Nature       Date:  1986 Feb 27-Mar 5       Impact factor: 49.962

6.  Anticonvulsant action of beta-kainic acid in mice. Is beta-kainic acid an N-methyl-D-aspartate antagonist?

Authors:  L Turski; B S Meldrum; J F Collins
Journal:  Brain Res       Date:  1985-06-10       Impact factor: 3.252

7.  Glycine potentiates the NMDA response in cultured mouse brain neurons.

Authors:  J W Johnson; P Ascher
Journal:  Nature       Date:  1987 Feb 5-11       Impact factor: 49.962

  7 in total
  9 in total

Review 1.  A scientific rationale for protective therapy in Parkinson's disease.

Authors:  C W Olanow
Journal:  J Neural Transm Gen Sect       Date:  1993

Review 2.  Molecular pathways in cerebral ischemia: cues to novel therapeutic strategies.

Authors:  Brigitte Onténiente; Sowmyalakshmí Rasika; Alexandra Benchoua; Christelle Guégan
Journal:  Mol Neurobiol       Date:  2003-02       Impact factor: 5.590

3.  Single dose propranolol does not affect physiologic or emotional reactivity to smoking cues.

Authors:  Gladys N Pachas; Jodi Gilman; Scott P Orr; Bettina Hoeppner; Sara V Carlini; Elisabeth B Grasser; Tsafrir Loebl; Johanna Nino; Roger K Pitman; A Eden Evins
Journal:  Psychopharmacology (Berl)       Date:  2014-11-22       Impact factor: 4.530

Review 4.  Novel NMDA receptor modulators: an update.

Authors:  Rose M Santangelo; Timothy M Acker; Sommer S Zimmerman; Brooke M Katzman; Katie L Strong; Stephen F Traynelis; Dennis C Liotta
Journal:  Expert Opin Ther Pat       Date:  2012-09-26       Impact factor: 6.674

5.  Kynurenic acid and 5,7-dichlorokynurenic acids improve social and object recognition in male rats.

Authors:  Z Hlinák; I Krejci
Journal:  Psychopharmacology (Berl)       Date:  1995-08       Impact factor: 4.530

Review 6.  Potentiation of the NMDA receptor in the treatment of schizophrenia: focused on the glycine site.

Authors:  Seong S Shim; Michael D Hammonds; Baik S Kee
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2007-09-27       Impact factor: 5.270

7.  NMDA receptor binding in focal epilepsies.

Authors:  C J McGinnity; M J Koepp; A Hammers; D A Riaño Barros; R M Pressler; S Luthra; P A Jones; W Trigg; C Micallef; M R Symms; D J Brooks; J S Duncan
Journal:  J Neurol Neurosurg Psychiatry       Date:  2015-05-19       Impact factor: 10.154

8.  Autoantibodies to NR2A Peptide of the Glutamate/NMDA Receptor in Patients with Seizure Disorders in Neuropsychiatric Systemic Lupus Erythematosus.

Authors:  Yan Yang; Chao Yuan; Shu-Qun Shen; Xue-Er Wang; Qing-Hua Mei; Wen-Qing Jiang; Qin Huang
Journal:  Mediators Inflamm       Date:  2017-01-05       Impact factor: 4.711

9.  Memory Enhancement with Kynurenic Acid and Its Mechanisms in Neurotransmission.

Authors:  Diána Martos; Bernadett Tuka; Masaru Tanaka; László Vécsei; Gyula Telegdy
Journal:  Biomedicines       Date:  2022-04-05
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.